An interventional study of Brief youth overdose prevention education and Usual standard of care in Overdose, sponsored by Boston Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Boston Medical Center · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Drug Overdose with a site in United States — 17 open to participants now, 28 under way, none of them phase 3. Drug Overdose · United States.
Among the 72 studies in Drug Overdose with a site in United States, this one is the 52nd largest by enrollment of the 58 interventional ones that give a count, is one of 6 that started in 2025, is one of 51 with no phase, reaches primary completion later than 8 of the 27 other live ones, and was the 60th registered.
104 studies on the registry are indexed under Drug Overdose; 22 are open to participants now.
Browse Drug Overdose studies →17 of the 72 studies in Drug Overdose with a site in United States are open now. Recruiting first, the newest first:
Boston Medical Center · Sites in United States
Ages 13+
San Francisco Department of Public Health · Sites in United States
Ages 18+ · Healthy volunteers
University of Wisconsin, Madison · Sites in United States
Ages 18+
Michele Staton · Sites in United States
Ages 18+ · Women only · Healthy volunteers
NYU Langone Health · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Drug Overdose studies recruiting now, 12 (92%) set no upper age limit and 1 (8%) stops at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 13 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 124 across 76 interventional studies indexed under Drug Overdose.
Median enrollment 182 across the 58 interventional studies, 217 across the 14 observational. Of the 40 that completed or were terminated, 18 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 72 have an industry lead sponsor. The 10 most frequent:
Boston Medical Center is the lead sponsor of 323 studies on the registry; 33 are open to participants now.
Of its 34 completed or terminated interventional studies of FDA-regulated products, 28 (82%) have results posted.
Boston Medical Center has 2 studies filed under Drug Overdose — fewer than ten, so there is no comparison to draw.
8 of the studies in Drug Overdose with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07022717Boston Medical CenterA Universal Primary Care Based Intervention to Reduce Youth Overdose Risk | 2026-11 |
| NCT05320835Johns Hopkins Bloomberg School of Public HealthA Setting Focus Overdose Prevention Intervention | 2026-12-01 |
| NCT06236087NYU Langone HealthOverdose Prevention Centers and Behavioral Health | 2026-12-31 |
| NCT07170072NYU Langone HealthShelter HArm Reduction Evaluation | 2027-03-31 |
| NCT05657106April M YoungKentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk | 2027-05-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 72 studies in Drug Overdose with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Adolescent (ages 10-19) overdose deaths are the third leading cause of pediatric death and continue to rise in the United States. Healthcare providers have regular and trusted relationships with youth and have experience in providing public health injury prevention counseling. Youth have different motivations for using drugs, and many who experience fatal overdose do not have a history of opioid use. Primary care pediatric providers regularly provide developmentally appropriate injury prevention counseling for leading causes of pediatric fatal and nonfatal injury such as drowning prevention and firearms safety. However, there are no recommended, evidence-based overdose prevention interventions for youth, including in health care settings, even though research supports pediatricians and youth-serving clinicians providing harm reduction strategies such as naloxone distribution and overdose education. Among adults, overdose prevention education reduces overdose, is cost-effective, and can be learned by laypersons. Content commonly includes awareness of fentanyl in the drug supply, risk reduction (e.g., not using alone, risks of polysubstance use), and how to recognize and respond to an overdose, including the use of naloxone.
This study is a pilot two-arm cluster randomized controlled trial (RCT) of a brief overdose prevention education intervention that will be developed in collaboration with the Community Advisory Board (CAB). The primary outcome of this study is to assess the feasibility and acceptability of the brief youth overdose prevention intervention as measured by provider feasibility and acceptability as well as youth acceptability.
The criteria were revised on the registry on Nov 12, 2026. See what changed
Inclusion Criteria for providers:
Exclusion Criteria for providers:
Inclusion criteria for youth:
Exclusion criteria for youth:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Providers randomized to the intervention group will complete a 45-minute intervention training. The training will occur either in person or via videoconference and include overdose prevention education, the pilot brief overdose prevention education intervention, intervention practice, and how to complete the fidelity checklist to be completed at the end of each visit.
Behavioral: Brief youth overdose prevention education
Providers randomized to the control group will provide usual care to youth during comprehensive physical exams (CPEs) or follow-up clinical appointments.
Other: Usual standard of care
Providers in the intervention group will inform youth participants about: the risk factors for overdose, how to recognize an overdose, and how to respond to an overdose. Providers in the intervention group will also educate youth participants on naloxone use and provide assistance with accessing naloxone
Youth participants will be provided usual care by providers in the control group. As part of usual care, providers may educate youth participants on naloxone use and provide assistance with accessing naloxone.
Provider feasibility of the brief overdose prevention education intervention
Providers in the intervention arm will complete a checklist after all comprehensive physical exams (CPEs) or follow-up clinical appointments with youth ages 13 to 26 years. The checklist will assess which components of the intervention the provider was able to deliver during the visit.
Time frame: 6 months
Provider acceptability of the brief overdose prevention education intervention
Providers in the intervention group will complete 8 questions based on the Theoretical Framework of Acceptability (TFA) acceptability questionnaire on a 5-point Likert scale. The measure will be collected post-intervention training and after all youth have received the intervention
Time frame: 6 months
Youth feasibility of the brief overdose prevention education intervention
Youth in the intervention arm will complete a checklist after their CPEs or follow-up clinical appointments. The checklist will assess which components of the intervention their provider was able to deliver during the visit.
Time frame: 6 months
Youth knowledge of risk associated with exposure to fentanyl and other emerging drugs
Assessed using a 4-point Likert scale question adapted from the Monitoring the Future (MTF) survey measuring perceived risk of harm from taking prescription medication that was not prescribed or taking medication other than prescribed.
Time frame: Baseline, 2 weeks, 6-months
Youth knowledge of strategies to reduce overdose risk
Assessed using a 4-point Likert scale questions adapted from the Monitoring the Future (MTF) survey measuring perceived risk associated with using more than one substance at a time and using substances while alone. Possible scores range from 1 (no risk) to 4 (great risk), with higher scores indicating greater perceived risk of harm (a better outcome).
Time frame: Baseline, 2 weeks, 6-months
Youth's ability to recognize an opioid overdose
Assessed using a question adapted from the Opioid Overdose Knowledge Scale (OOKS) evaluating participants' ability to identify signs of an opioid overdose.
Time frame: Baseline, 2 weeks, 6-months
Youth's ability to respond to an opioid overdose
Assessed using a question adapted from the Opioid Overdose Knowledge Scale (OOKS) evaluating participants' knowledge of steps in opioid overdose response.
Time frame: Baseline, 2 weeks, 6-months
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Nov 2026, 15 months after the start.
Of 47 non-industry interventional studies with no phase under Drug Overdose, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 49. This study's planned 15 months is below that.
Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 13 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.